Ionis Antisense Platform Safety Questioned After Thrombocytopenia Seen In Studies

GSK halts plans for Phase III study of antisense candidate in FAC due to FDA clinical hold for findings of reduced platelet counts in another Phase III trial; Ionis reveals similar findings in Phase III study of another antisense compound.